LAST WEEK TODAY!

A summary of what was published on ProstateWarriors.com during the past week

Hello fellow warriors! This week is focused mainly on clinical research. Stay strong and fight on!

As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE.​

Clinical Research

• Phase 1 Trial: IL-18–Armored STEAP1 CAR T Cells for mCRPCA​
  Phase 1 clinical trial is evaluating IL-18–armored STEAP1 CAR T cells (PRO CAR-202) to overcome the immunosuppressive tumor microenvironment and antigen heterogeneity in metastatic castration-resistant prostate cancer (mCRPC). STEAP1 is a cell-surface protein overexpressed across bone, lymph-node, and visceral metastases in lethal mCRPC, exhibiting minimal presence in normal tissues. By engineering the CAR T cells to constitutively secrete the pro-inflammatory cytokine interleukin-18 (IL-18), this approach enhances T-cell expansion and persistence, lowers exhaustion, and recruits innate immune effectors like NK cells and macrophages to generate potent antitumor responses.​
  ​
• Phase 1/2 Trial: Multikinase Inhibitor Tinengotinib (TT-00420) in mCRPCA​
  US-based Phase 1/2 trial published in Clinical Cancer Research evaluated tinengotinib (TT-00420), an oral multikinase inhibitor designed to simultaneously target Aurora kinases A/B, FGFR1–3, VEGFR2, and JAK1/2 in treatment-resistant prostate cancer. Among 15 heavily pretreated mCRPC patients, tinengotinib achieved an objective radiographic response rate of 33.3% with a manageable safety profile predominantly characterized by hypertension. Exploratory genomic findings indicated that MYC alterations were associated with shorter progression-free survival, whereas reductions in circulating tumor DNA (ctDNA) demonstrated clear pharmacodynamic target engagement.​
  ​
• Phase 3 Trial: STAMINA Lifestyle Intervention During ADT​
  Published in The Lancet Oncology, the Phase 3 randomized STAMINA trial evaluated a 12-month supervised exercise and dietary intervention among 700 men receiving androgen deprivation therapy (ADT). The lifestyle program was superior to standard care across both primary endpoints, reducing deterioration in prostate cancer-specific quality of life by 26% (FACT-P score) and worsening fatigue by 30% (FACIT-F score). Participants demonstrated high intervention adherence (>80%), and economic modeling confirmed the program’s cost-effectiveness.​
  ​
• Dietary Fat Composition and Survival After Nonmetastatic Prostate Cancer​
  An observational cohort study published in JAMA Network Open followed 4,884 men with nonmetastatic prostate cancer for a median of 12.8 years to assess how postdiagnosis dietary fat relates to long-term survival. Higher postdiagnosis consumption of saturated and animal fats was associated with a 24% higher risk of all-cause mortality and a 42% higher risk of cardiovascular death, though fat composition did not directly alter prostate-cancer-specific mortality. Replacing 10% of total daily calories from animal fat with plant-based fat reduced all-cause mortality risk by 16%, while substituting 5% of saturated fat calories with monounsaturated fat lowered all-cause death risk by 20%.
  ​

Preclinical Research & Reviews

• Reading the DNA Fingerprints of Prostate Cancer​
  A whole-genome sequencing study published in Nature identified eight Integrated Mutational Footprints (IMFs) that capture the distinct biological processes driving DNA damage across primary prostate cancers. These signatures reflect underlying mechanisms such as mismatch-repair deficiency, reactive oxygen species (ROS) damage, androgen receptor (AR) activity, replication stress, APOBEC activity, and two forms of homologous recombination deficiency (canonical BRCA2-related and non-canonical CDK12-related). Four IMFs were associated with an increased risk of metastasis, and tumors exhibiting high levels of IMF6 (replication stress) responded better to AR pathway inhibitors than to taxane chemotherapy.
  ​
  ​

And…that’s all folks! For today at least!
Please let me know if there is anything I can improve in my newsletters, and let me know if you have enjoyed the podcast.

If this newsletter was delivered to your SPAM folder, make sure to let your email system know that it is not spam.
​
​
Have a great weekend!

Max